As Per the Report, the Europe Metabolomics Market is valued at USD 530 Million in 2019 and estimated to grow at a CAGR of 18.4%, to reach USD 1240 Million by 2024 during the forecast period 2019-2024.
Metabolomics is the considerable scale research of minute molecules, usually known as metabolites, inside cells, tissues or living beings. Aggregately, these tiny particles and their associations inside an organic framework are known as the metabolome. Therefore metabolomics characterizes the microscopic phenotype. Metabolomics is a skilled approach since metabolites and their concentration not like other "omics" measures, directly reflect the hidden biochemical movement and state of cells. The Europe Metabolomics market is emerging at an exceptionally quick speed.
Govt. financing and private funding are also reassuring the growth of this market. Metabolomics is in effect gradually sought after as they help in shrinking the hole between genotype and phenotype by offering a whole perspective of the cell working. Stable innovative advances and looks into will guarantee a proceeded with the development of this market and will decrease the effect of these restrictions in the future. Nonetheless, the unexplored markets in evolving countries will spur new progress open doors for market players.
This research report on the Europe Metabolomics Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
On the Basis of Application, the Biomarker Discovery segment had the largest share in 2016 in the global metabolomics market. Efficiency and reliability have been cited as the reason for the growth of biomarkers. However collaboration between biotechnology and pharmaceutical companies, the personalized medical segment is expected to have the highest CAGR.
On the Basis of the Region, Europe had the least CAGR during the forecast period. The reasons for the same might be government policies.
Top Companies leading the Europe Metabolomics Market Profiled in the Report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.) are the leaders in the North America Metabolomics market
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Metabolomic Instruments
5.1.1.1Separation Techniques
5.1.1.1.1 Gas Chromatography (GC)
5.1.1.1.2 Capillary Electrophoresis (CE)
5.1.1.1.3 High-performance Liquid Chromatography (HPLC)
5.1.1.1.4 Ultra-performance Liquid Chromatography (UPLC)
5.1.1.2 Detection Tools
5.1.1.2.1 Mass Spectrometry
5.1.1.2.2 Nuclear Magnetic Resonance Spectroscopy
5.1.1.2.3 Surface-Based Mass Analysis
5.1.2 Metabolomics Bioinformatics Tools and Services
5.1.2.1 Bioinformatics Tools & Databases
5.1.2.2 Bioinformatics Services
5.1.3 Y-o-Y Growth Analysis, By Product
5.1.4 Market Attractiveness Analysis, By Product
5.1.5 Market Share Analysis, By Product
5.2 Indication
5.2.1 Cancer
5.2.2 Cardiovascular Disorders
5.2.3 Inborn errors
5.2.4 Neurological Errors
5.2.5 Other Indications
5.2.4 Y-o-Y Growth Analysis, By Indication
5.2.5 Market Attractiveness Analysis, By Indication
5.2.6 Market Share Analysis, By Indication
5.3 Application
5.3.1 Nutrigenomics
5.3.2 Toxicology
5.3.3 Biomarker & Drug Discovery
5.3.4 Functional Genomics
5.3.5 Personalized Medicine
5.3.6 Other Applications
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Indication
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Waters Corporation (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Agilent Technologies, Inc. (U.S.)
8.3 Human Metabolome Technologies, Inc. (Japan)
8.4 Thermo Fisher Scientific, Inc. (U.S.)
8.5 LECO Corporation (U.S.)
8.6 Bruker Corporation (U.S.)
8.7 Shimadzu Corporation (Japan)
8.8 Metabolon Inc. (U.S.)
8.9 Danaher Corporation (U.S.)
8.10 Biocrates Life Sciences AG (Austria)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
